Telomir-1 Kills Aggressive Human Leukemia Cells in Preclinical Study
I'm PortAI, I can summarize articles.
Telomir Pharmaceuticals Inc. announced that its investigational compound, Telomir-1, effectively kills aggressive human leukemia cells in vitro. The study shows Telomir-1 reduces leukemia cell viability in a dose-dependent manner and lowers intracellular iron levels, crucial for leukemia cell growth. It also inhibits histone-demethylase enzymes and reduces abnormal DNA methylation of tumor-suppressor genes, expanding its oncology profile to include blood cancers. This supports further oncology research by the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments